Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Visual Impairment and Cardiovascular Risk Factors in Hispanic and Latino Adults.

JAMA network open·2026
Same author

The Impact of Socioeconomic Factors on Pediatric Keratoplasty Outcomes: A Decade of Our Experience at a Tertiary Eye Care Center in South India.

Cornea·2026
Same author

Correction: Toward a clearer vision: epidemiology and symptom-based clinical patterns of dry eye disease in the Saudi population.

Frontiers in medicine·2026
Same author

Toward a clearer vision: epidemiology and symptom-based clinical patterns of dry eye disease in the Saudi population.

Frontiers in medicine·2026
Same author

Prevention and early intervention screening for inherited ocular diseases in Saudi Arabia: a national perspective.

Frontiers in ophthalmology·2026
Same author

Role of Ocular Pathology in Understanding Glaucoma.

Ocular oncology and pathology·2026
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Related Experiment Video

Updated: Jun 19, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Bimatoprost - a review.

A Jayaprakash Patil1, Thasarat S Vajaranant, Deepak P Edward

  • 1Summa Health System, Department of Ophthalmology, Akron, OH, USA.

Expert Opinion on Pharmacotherapy
|October 31, 2009
PubMed
Summary
This summary is machine-generated.

Bimatoprost effectively lowers intraocular pressure (IOP) in glaucoma patients by increasing fluid outflow. This prostamide analog offers sustained IOP reduction and is a cost-effective treatment option.

Related Experiment Videos

Last Updated: Jun 19, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Area of Science:

  • Ophthalmology
  • Pharmacology

Background:

  • Glaucoma and ocular hypertension require effective intraocular pressure (IOP) management.
  • Bimatoprost is a synthetic prostamide analog used to treat these conditions.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of bimatoprost in lowering IOP.
  • To compare bimatoprost with other glaucoma treatments.

Main Methods:

  • Topical administration of 0.03% bimatoprost solution once daily.
  • Monitoring of IOP reduction over a 24-hour period.
  • Comparison with timolol and other prostaglandin analogs.

Main Results:

  • Sustained IOP reduction of 7-8 mmHg over 24 hours.
  • Demonstrated greater efficacy than timolol in some studies.
  • Effective when used in combination with other glaucoma medications.
  • Common side effects include reversible conjunctival hyperemia, periorbital pigmentation, and ocular discomfort.

Conclusions:

  • Bimatoprost is an effective treatment for lowering IOP in glaucoma and ocular hypertension.
  • It offers a favorable safety profile with generally reversible side effects.
  • Pharmacoeconomic data suggest bimatoprost is a cost-effective therapeutic option.